Kensuke Oikawa
YOU?
Author Swipe
View article: Soluble <scp>CD27</scp> as a predictive biomarker for intra‐tumoral <scp>CD70</scp>/<scp>CD27</scp> interaction in nasopharyngeal carcinoma
Soluble <span>CD27</span> as a predictive biomarker for intra‐tumoral <span>CD70</span>/<span>CD27</span> interaction in nasopharyngeal carcinoma Open
In CD70‐expressing tumors, the interaction of CD70 on tumor cells with its lymphocyte receptor, CD27, is thought to play a role in immunosuppression in the tumor microenvironment and elevated serum levels of soluble CD27 (sCD27). Previous …
View article: Collision tumor of spindle cell lipoma arising from perirenal tissue and acquired cystic disease‐associated renal cell carcinoma: A rare case report
Collision tumor of spindle cell lipoma arising from perirenal tissue and acquired cystic disease‐associated renal cell carcinoma: A rare case report Open
Introduction Collision tumors are a rare phenomenon defined as two or more histologically distinct tumors that are in contact with each other. Case presentation The patient was a man with a history of end‐stage diabetic nephropathy under h…
View article: Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy Open
View article: A tumor metastasis‐associated molecule <scp>TWIST1</scp> is a favorable target for cancer immunotherapy due to its immunogenicity
A tumor metastasis‐associated molecule <span>TWIST1</span> is a favorable target for cancer immunotherapy due to its immunogenicity Open
Although neoantigens are one of the most favorable targets in cancer immunotherapy, it is less versatile and costly to apply neoantigen‐derived cancer vaccines to patients due to individual variation. It is, therefore, important to find hi…
View article: CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes Open
Activation of STING signaling plays an important role in anti-tumor immunity, and we previously reported the anti-tumor effects of STING through accumulation of M1-like macrophages in tumor tissue treated with a STING agonist. However, mye…
View article: SMARCB1 (INI1) retained but SMARCA4 (BRG1) negative atypical teratoid/rhabdoid tumor arising at the bilateral cerebellopontine angles: a case report
SMARCB1 (INI1) retained but SMARCA4 (BRG1) negative atypical teratoid/rhabdoid tumor arising at the bilateral cerebellopontine angles: a case report Open
Most atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system shows an inactivation of SMARCB1 (INI1) and is considered as the hallmark of this neoplasm. However, AT/RT could exceptionally rarely present retained SMARCB1 (INI…
View article: A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy Open
Recent studies have revealed that tumor cells decrease their immunogenicity by epigenetically repressing the expression of highly immunogenic antigens to survive in immunocompetent hosts. We hypothesized that these epigenetically hidden “s…
View article: A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment
A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment Open
View article: Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma Open
Placenta-specific 1 (PLAC1) is expressed primarily in placental trophoblasts but not in normal tissues and is a targetable candidate for cancer immunotherapy because it is a cancer testis antigen known to be up-regulated in various tumors.…
View article: A 47-Year-Old Woman With Pulmonary Nodules and Facial Hemispasms
A 47-Year-Old Woman With Pulmonary Nodules and Facial Hemispasms Open
View article: Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer Open
View article: Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma
Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma Open
Although cisplatin (CDDP) has been used as a major chemotherapeutic drug for head and neck squamous cell carcinoma (HNSCC), its impact on T-cell functions is controversial. Therefore, we investigated the immunologic effects of CDDP and ant…
View article: PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma Open
The cancer immunotherapy targeting PD-L1 as a helper T-cell antigen would be a rational strategy for HNSCC patients.
View article: Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma
Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma Open
The human T cell receptor is capable of distinguishing between normal and post-translationally modified peptides. Because aberrant phosphorylation of cellular proteins is a hallmark of malignant transformation, the expression of the phosph…
View article: Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb
Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb Open
Despite recent advances in treatment for melanoma patients through using immune checkpoint inhibitors, these monotherapies have limitations and additional treatments have been explored. Type I IFNs have been used to treat melanoma and poss…
View article: Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy Open
View article: Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site
Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site Open
View article: Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy
Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy Open
Tumor immune escape has been a major problem for developing effective immunotherapy. The human leukocyte antigen G (HLA-G) is a non-classical MHC class I molecule whose primary function is to protect the fetus from the mother's immune syst…
View article: Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma
Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma Open
HER-3 expression has been reported to act as an important oncoprotein in head and neck squamous cell carcinoma. This protein is known to control tumor proliferation and acquisition of resistance by tumor cells towards EGFR inhibitors, ther…
View article: c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma Open
Background: The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the …